TickerKhojPharmaceuticals · Pharmaceuticals: Generic · NSE: JAGSNPHARM · data 2026-11-02
Jagsonpal Pharmaceuticals Ltd.
In plain words
Price: 18.3% below its 52-week high of ₹264.5.
Delivery: 48.6% of traded shares were kept for delivery over the last 10 sessions, against 49.1% over the last 60.
Latest results: a net profit of ₹12 cr for the quarter ended Sept 2026 (-2.2% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹316 cr |
| Net profit (last 12 months) | ₹45 cr |
| Sales growth, 3 years (yearly) | 6.7% |
| Profit growth, 3 years (yearly) | 17.3% |
At a glance
Promoters 68.8% (+1.3 pts in a year), pledged 0.0%, institutions 3.8%.
P/E 32.4, P/B 5.9, dividend yield 1.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 16.7%, ROCE 18.1%, operating margin 16.6%: how much profit it earns on the money it uses.
Debt/equity 0.03, Profit growth 17.3% and sales growth 6.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Profit grew 17.3% a year over 3 years.
- Promoters raised their holding by 1.3 points in a year.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
JAGSNPHARM Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹96.37 crore.
Net profit was ₹12.29 crore.
Operating margin was 17.5%.
EPS was ₹1.86.
JAGSNPHARM के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹96.37 करोड़।
शुद्ध मुनाफ़ा: ₹12.29 करोड़।
ऑपरेटिंग मार्जिन: 17.5%।
EPS: ₹1.86।
JAGSNPHARMના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹96.37 કરોડ.
ચોખ્ખો નફો: ₹12.29 કરોડ.
ઓપરેટિંગ માર્જિન: 17.5%.
EPS: ₹1.86.
Written from the filed numbers. Not a recommendation.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 48.2% over the last 20 sessions vs 19.5% in the 40 before (2.47x); shares delivered per day 0.66x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend ● Split
- 28 Oct 26Results Q2 FY27 results: net profit ₹12.3 cr -0.5% next session
- 4 Sept 26Dividend Dividend ₹4 (ex-date) -1.6% next session
- 29 Jul 26Results Q1 FY27 results: profit +22.2% YoY +5.3% next session
- 27 Apr 26Results Q4 FY26 results: profit +33.1% YoY +3.2% next session
- 21 Jan 26Results Q3 FY26 results: profit −65.8% YoY -4.0% next session
- 3 Nov 25Results Q2 FY26 results: profit +9.7% YoY -2.8% next session
- 12 Sept 25Dividend Dividend ₹2.5 (ex-date) +0.9% next session
- 26 Jul 25Results Q1 FY26 results: profit +102.4% YoY +11.2% next session
- 6 May 25Results Q4 FY25 results: profit +85.4% YoY -12.0% next session
- 23 Jan 25Results Q3 FY25 results: profit +707.8% YoY +7.1% next session
- 8 Jan 25Split Split: face value ₹5 → ₹2 (ex-date) -11.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹96 cr | ₹12 cr | -2.2% | 17.5% | 1.86 |
| Jun 2026 | ₹82 cr | ₹13 cr | +22.2% | 21.0% | 2 |
| Mar 2026 | ₹64 cr | ₹9 cr | +33.1% | 17.4% | 1.25 |
| Dec 2025 | ₹73 cr | ₹11 cr | -65.8% | 22.3% | 1.67 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 68.81% | 69.05% | 67.89% | 67.39% |
| Foreign institutions (FII) | 2.14% | 2.30% | 2.44% | 2.12% |
| Domestic institutions (DII) | 1.65% | 0.62% | 0.22% | 0.15% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 16.28% | 15.95% | 17.27% | 16.00% |
| Number of shareholders | 26,537 | 24,181 | 26,264 | 24,895 |
Common questions
What was Jagsonpal Pharmaceuticals Ltd.'s latest quarterly profit?
Jagsonpal Pharmaceuticals Ltd. reported a net profit of ₹12 cr for the quarter ended Sept 2026 (-2.2% on the same quarter a year earlier), on revenue of ₹96 cr.
How much do promoters hold in Jagsonpal Pharmaceuticals Ltd.?
Promoters held 68.81% of Jagsonpal Pharmaceuticals Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Jagsonpal Pharmaceuticals Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.03, which is very low.
What is Jagsonpal Pharmaceuticals Ltd.'s P/E ratio?
About 32.4, based on the last 12 months' earnings and a price of ₹215.99 (data 2026-11-02).
What is the 52-week high and low of Jagsonpal Pharmaceuticals Ltd.?
The 52-week high is ₹264.5 and the 52-week low is ₹155.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd. | ₹215.99 | ₹1,433 cr | 32.4 | 5.9 | 16.7% | 18.1% | 0.03 | -2.5% |
| NGL Fine-Chem Ltd. | ₹2,574 | ₹1,576 cr | 27.8 | — | 15.7% | 17.1% | 0.37 | +68.8% |
| Accent Microcell Limited | ₹634.3 | ₹1,533 cr | 26.7 | 5 | 18.7% | 22.7% | 0 | +130.7% |
| Amrutanjan Health Care Limited | ₹496.85 | ₹1,452 cr | 26.6 | — | 16.6% | 17.9% | 0 | -31.3% |
| Bharat Parenterals Ltd. | ₹2,026.8 | ₹1,397 cr | 1,122.9 | 4.2 | -2.5% | -4.2% | 0.45 | +44.8% |
| Anlon Healthcare Limited | ₹25.33 | ₹1,378 cr | 37.7 | 5.2 | 18.4% | 24.3% | 0.19 | +95.0% |
Compare JAGSNPHARM with NGLFINE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open JAGSNPHARM in TickerKhoj →